Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 466 participants.

Also called NCT05199662

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 466 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05199662
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05199662. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-20 (actual); primary completion 2026-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT
Acronym
EXTEND-IV
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Intravenous tenecteplase
Intervention (Drug)
Placebo
Lead sponsor
Hospital Moinhos de Vento (class: other)
Collaborator
Ministry of Health, Brazil (class: other government)
Collaborator
Boehringer Ingelheim (class: industry)
Collaborator
Brainomix Limited (class: industry)
Collaborator
iSchemaView, Inc (class: not stated)

Record details

Record id
cardio:ct-nct05199662
Content hash
8e4861c4cfe027b11240775fe291312363d7b7a3df177c9041037d263669a123